Strategy and Full Year 2021 Trading Update and Interview with David Allmond

Full year revenue and EBITDA in line with expectationsCommitted to becoming a leading, global clinical diagnostics company Paris, France and Camberley, UK – 25 January 2022 – Novacyt (EURONEXT GROWTH: ALNOV; AIM: NCYT), an international specialist in clinical diagnostics, announces an unaudited trading update for the year ended 31 December 2021, together with a strategy

Visit Page

Approval of COVID-19 test in the UK under CTDA legislation

Paris, France and Camberley, UK – 26 November 2021 – Novacyt (EURONEXTGROWTH: ALNOV; AIM: NCYT), an international specialist in clinical diagnostics,announces that, further to the announcement on 2 November 2021, the Company’sgenesig® COVID-19 Real-Time PCR test has been approved in the UK under the UK HealthSecurity Agency’s Medical Devices (Coronavirus Test Device Approvals) (Amendment)Regulations 2021

Visit Page

Validation of COVID-19 tests in the UK under CTDA legislation

Paris, France and Camberley, UK – 2 November 2021 – Novacyt (EURONEXT GROWTH: ALNOV; AIM: NCYT), an international specialist in clinical diagnostics, announces an update on the availability of its COVID-19 tests in the UK following implementation of the UK Health Security Agency’s Medical Devices (Coronavirus Test Device Approvals) (Amendment) Regulations 2021 (“CTDA”). http://novacyt.com/wp-content/uploads/2021/11/Novacyt-Validation-of-COVID-19-tests-in-the-UK-under-CTDA-FINAL-ENG.pdf

Visit Page

Notice of AGM

Paris, France and Camberley, UK – 20 August 2021 – Novacyt (EURONEXT GROWTH: ALNOV; AIM: NCYT), an international specialist in clinical diagnostics, announces that its Annual General Meeting (AGM) will be held as a closed meeting at 2pm CEST/1pm BST on Wednesday, 29 September 2021. The AGM comprises both ordinary and extraordinary general meetings. http://novacyt.com/wp-content/uploads/2021/08/Novacyt-Notice-of-AGM-Aug-2021.pdf

Visit Page

Half Year Update

Investor meeting at 13:00 BST / 14:00 CEST Paris, France and Camberley, UK – 18 August 2021 – Novacyt (EURONEXT GROWTH: ALNOV; AIM: NCYT), an international specialist in clinical diagnostics, announces a half year update in advance of its investor meeting today. http://novacyt.com/wp-content/uploads/2021/08/Novacyt-half-year-update.pdf

Visit Page

Notice of investor meeting

Paris, France and Camberley, UK – 5 August 2021 – Novacyt (EURONEXT GROWTH: ALNOV; AIM: NCYT), a leading international specialist in clinical diagnostics, announces that it will hold an investor meeting on Wednesday, 18 August 2021, at 13:00 BST / 14:00 CEST. http://novacyt.com/wp-content/uploads/2021/08/Novacyt-Notice-of-Investor-meeting-.pdf

Visit Page

Publication of Annual Report

Paris, France and Camberley, UK – 29 June 2021 – Novacyt S.A. (EURONEXT GROWTH: ALNOV; AIM: NCYT), an international specialist in clinical diagnostics, announces that the Company’s Annual Report and Accounts (“Annual Report”) for the year ended 31 December 2020 has been published and uploaded to the Company’s website. The Annual Report has been posted

Visit Page

Launch of two new PCR COVID-19 assays

Paris, France and Camberley, UK – 3 June 2021 – Novacyt (EURONEXT GROWTH: ALNOV; AIM: NCYT), an international specialist in clinical diagnostics, announces the launch of two new polymerase chain reaction (PCR) assays, expanding its genesig® COVID-19 and SNPsig® SARS-CoV-2 variant detection portfolios. http://novacyt.com/wp-content/uploads/2021/06/Novacyt-Launch-of-two-new-PCR-COVID-19-assays-final.pdf

Visit Page

Launch of VersaLab™ Portable

Paris, France and Camberley, UK – 26 May 2021 – Novacyt (EURONEXT GROWTH: ALNOV; AIM: NCYT), an international specialist in clinical diagnostics, announces the expansion of its VersaLab™ portfolio with the launch of VersaLab™ Portable to provide an additional level of support in near-patient testing environments. http://novacyt.com/wp-content/uploads/2021/05/Expansion-of-VersaLab-final-ENGLISH-.pdf

Visit Page

Inclusion of SNPsig® SARS-CoV-2 PCR genotyping portfolio in the NHS England Framework and expansion of SNPsig® product range

Paris, France and Camberley, UK – 17 May 2021 – Novacyt (EURONEXT GROWTH: ALNOV; AIM: NCYT), an international specialist in clinical diagnostics, announces that the Company’s SNPsig® SARS-CoV-2 polymerase chain reaction (PCR) genotyping portfolio has been included in the NHS England Framework for detecting Variants of Concern (VoC). Novacyt also announces the launch of two

Visit Page